Predictive Oncology to Participate in Upcoming San Francisco Conferences

Rhea-AI Summary

Predictive Oncology Inc. (NASDAQ: POAI) CEO to present at Biotech Showcase and participate in LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024

PITTSBURGH, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024, at 4:00 p.m. PT. Company management will also participate in the 13^th Annual LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024. Please see below for additional details about the events and how to request a one-on-one meeting with management.

Presentation at Biotech Showcase

• Presentation Date: Tuesday, January 9, 2024, 4:00 p.m. PT
• Location: Hilton San Francisco Union Square, Yosemite-A

One-on-One Meetings
Predictive Oncology senior management will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. Meetings can be requested as follows:

• Biotech Showcase: link here
• BIO Partnering @ JPM Week 2024: link here
• 13^th Annual LifeSci Partners Corporate Access Event: link here
• Direct outreach to tim@lifesciadvisors.com

About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA. 

Investor Relations Contact
Tim McCarthy  
LifeSci Advisors, LLC  
tim@lifesciadvisors.com

Forward-Looking Statements: 
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.   

What is the upcoming event Predictive Oncology Inc. (NASDAQ: POAI) CEO will be presenting at?

Predictive Oncology Inc. (NASDAQ: POAI) CEO will be presenting at the Biotech Showcase in San Francisco, CA, on January 9, 2024, at 4:00 p.m. PT.

What other events will Predictive Oncology Inc. (NASDAQ: POAI) management be participating in?

Company management will also participate in the 13th Annual LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024.